Peptide Attorney in Charlotte, North Carolina
Legal counsel for peptide clinics, longevity practices, compounding relationships and telehealth platforms, from an attorney who has built and exited businesses in regulated markets.
Peptide therapy sits where several regulatory systems meet, none designed with the others in mind: state medical-practice, telemedicine and corporate-practice rules, federal drug and compounding law, and advertising enforcement. Most businesses in this space are built by clinicians and operators who understand the medicine and the market, but not the legal structure that a board complaint, a pharmacy audit or a regulator’s inquiry will test.
DPS Law is a Charlotte law and business consulting firm. David P. Sheehan has practiced law for nearly two decades and concentrates his practice on business law and emerging markets, with particular depth in the peptide industry across its channels: manufacturers and laboratories, physicians and clinics, management services organizations and telehealth platforms. He is also an equity holder in, and serves on the board of directors of, a peptide company.
Nothing on this page says what any therapy does, or whether it is appropriate for anyone. Those are medical questions and they belong to a clinician. What is set out here is the regulatory position: what may lawfully be prepared, by whom, under which agreement, and what may lawfully be said about it.
Who we represent
Peptide and longevity clinics
Launching or restructuring in Charlotte and across North Carolina.
Physicians, NPs and PAs
Offering peptide therapy inside an existing practice or med spa.
Non-physician founders and investors
Building and running the business side of a clinic through a management services organization, alongside a clinician-owned professional entity.
Telehealth platforms
And the management companies behind them, offering peptide therapy through licensed prescribers and pharmacies in multiple states.
Compounding pharmacies and 503B outsourcing facilities
Negotiating with clinics and prescribers.
Research-use-only peptide sellers
Reassessing labeling, marketing and sales practices against the FDA’s intended-use standard.
How we help peptide businesses
MSO / PC structuring in North Carolina
A business practicing medicine in North Carolina must be owned by holders of active North Carolina licenses, or by one of the combinations G.S. 55B-14 permits, such as a physician together with a physician assistant or nurse practitioner. That is the Medical Board’s position on the corporate practice of medicine, amended September 2025. A non-licensee investor or operator therefore does not own the clinical entity. A management services organization can contract with it for the non-clinical side of the business on arm’s-length terms, and the management fee, the control provisions and the line around clinical decisions have to be drafted so that boundary holds. We build the entity set, the management services agreement and the supervision arrangements. More on MSO and friendly-PC structuring and who may own a clinic in North Carolina.
Compounding and FDA peptide status
Under section 503A of the Federal Food, Drug, and Cosmetic Act, a pharmacy may compound from a bulk substance only if it has a USP or National Formulary monograph, is a component of an FDA-approved drug, or appears on the FDA’s 503A bulks list. A 503B outsourcing facility needs the substance on the 503B bulks list or the drug on the FDA’s shortage list. Several popular peptides meet none of those tests today. The position moved twice in 2026: in April the FDA took twelve peptides, BPC-157 among them, out of Category 2 of its interim policy, and in July its Pharmacy Compounding Advisory Committee recommended six of them for the 503A bulks list. Neither step changes the law, which takes notice-and-comment rulemaking that the FDA had not begun as of September 2026. We advise clinics on where each product sits (FDA-approved, eligible under section 503A or 503B, or not lawfully compoundable today), review pharmacy agreements, and build sourcing, prescribing protocols and records around that position, revisiting them each time it moves. The FDA’s own list: Bulk Drug Substances Used in Compounding Under Section 503A.
GLP-1 and weight-loss programs
The semaglutide and tirzepatide shortages are over. The FDA declared them resolved in December 2024 and February 2025, the transition periods for compounders ended in 2025, and in August 2026 the Fifth Circuit upheld both decisions. In April 2026 the FDA also proposed leaving semaglutide, tirzepatide and liraglutide off the 503B bulks list used by outsourcing facilities. We help clinics rebuild GLP-1 programs and pharmacy relationships around that position and bring patient-facing materials in line with what the FDA allows. See the FDA’s 503B proposal on semaglutide and tirzepatide.
Telehealth and multi-state expansion
Offering peptide therapy through telehealth means meeting the medical practice, telemedicine and licensure rules of each state where a patient is located, not only the state where the company is formed. We map the state footprint, structure the professional entities and provider networks, and draft the intake, consent and prescribing protocols. Where another state’s law governs, the firm works with counsel admitted there.
Advertising, claims and regulatory exposure
“Anti-aging,” “healing,” “performance” and weight-loss claims draw attention from the FDA, the FTC, state attorneys general and medical boards. The FDA has sent repeated rounds of warning letters to telehealth companies whose marketing implied compounded GLP-1s were the same as FDA-approved drugs. We review websites, social content and provider scripts before they publish, because advertising is the part regulators read first.
Research-use-only peptide sales
A “research use only” label is not a safe harbor. In warning letters issued in August 2026, the FDA told online peptide sellers that their own websites, including bacteriostatic water, peptide guides and dosage calculators sold alongside the products, showed the products were intended for human use and were unapproved new drugs despite research-use disclaimers. We assess how the business actually operates, from product pages and dosing content to what ships with an order, and help restructure it where needed.
Capital, growth and exit
Beyond compliance, DPS Law handles the corporate side of scaling a peptide business: founder agreements, investor documents at the management-company level, clinic acquisitions structured so the clinical entity stays in licensed hands, and the diligence buyers run on healthcare targets. A structure that survives diligence is worth more than one that only survives launch. See legal structuring and capital raise support.
Why an attorney who has built and run a regulated business
Peptide work is not a paper exercise. The right answer on a supervision chain, a pharmacy agreement or a management fee depends on how the business actually runs. Mr. Sheehan founded and operated licensed cannabis businesses, raised capital at successive valuations and structured an eight-figure exit, and he serves on the board of a peptide company. Every matter is led by him, and where the work calls for a healthcare regulatory attorney, a CPA or an operator who has run your channel, the firm brings them in and remains your single point of contact.
Serving Charlotte, North Carolina and beyond
DPS Law is at 216 N McDowell St Ste 110-D, Charlotte, NC 28204, and works with peptide and longevity businesses across Mecklenburg County and the Charlotte region. Clients elsewhere in North Carolina and Virginia, and telehealth and multi-state matters, are handled remotely. Mr. Sheehan is admitted in North Carolina and Virginia; where another state’s law governs, the firm works with counsel admitted there.
Frequently asked questions
Can a non-physician own a peptide clinic in North Carolina?
Not the clinical practice itself. The North Carolina Medical Board’s position is that a business practicing medicine must be owned entirely by holders of active North Carolina licenses, or by one of the licensee combinations G.S. 55B-14 permits, such as a physician together with a physician assistant or nurse practitioner. A non-licensee can own a management services organization that contracts with that licensee-owned entity for the non-clinical side of the business on arm’s-length terms.
Are peptides like BPC-157 legal to prescribe in North Carolina?
Prescribing is a medical judgment, but sourcing is a regulatory question. BPC-157 has no FDA-approved version, no USP monograph, and is not on the FDA’s 503A bulks list, so as of September 2026 a pharmacy cannot lawfully compound it, even after the FDA’s April 2026 Category 2 change and the July 2026 advisory committee vote in its favor. A clinic needs to know where each substance sits before building a protocol around it.
Are peptides becoming legal to compound?
The process has started for some. In July 2026 an FDA advisory committee voted to recommend six peptides, BPC-157 among them, for the 503A bulks list. That recommendation does not bind the FDA, and a substance is added only through notice-and-comment rulemaking, which had not begun as of September 2026. Until it is, those peptides still cannot lawfully be compounded.
Do I need an MSO if I am a physician opening my own clinic?
Often not at the outset. It depends on whether outside investors, a non-clinical business partner or a future sale are part of the plan. Outside investors cannot buy into the clinical entity itself: G.S. 55B-6 limits its shares to licensed professionals, and a non-compliant issuance or transfer is void. Where outside capital or an operator is part of the plan, putting a management services organization in place early lets them come in at that level later, without restructuring the clinical entity.
Can my Charlotte clinic sell peptides to patients in other states through telehealth?
Only by meeting the rules of each state where a patient is located. That usually means a prescriber licensed in, or registered with, that state, and compliance with its telemedicine and corporate-practice rules. Multi-state telehealth needs a state-by-state plan rather than a single national template, and where another state’s law governs, the firm works with counsel admitted there.
What does it cost to work with a peptide attorney?
Structuring work, including entity formation and the management services agreement, is scoped and priced before it starts. Ongoing compliance and advertising review run on a defined retainer. Hourly billing is reserved for litigation and genuinely open-ended matters.
Attorney advertising. This page is general information about the law as of September 2026, not legal advice, and reading it does not create an attorney–client relationship. The regulatory positions described here change, so confirm current status before relying on them. Prior results do not guarantee a similar outcome.
Peptide and longevity clinics, physicians and advanced practice providers, non-physician founders building through an MSO, telehealth platforms, compounding pharmacies and research-use sellers.
Scoped and fixed for structuring. Ongoing compliance and advertising review on a defined retainer.
A scoped call on what this actually needs, before anything is drafted.
Book a consultation or call (704) 222-4752